These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532 [TBL] [Abstract][Full Text] [Related]
3. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China. Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535 [TBL] [Abstract][Full Text] [Related]
4. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. Zeng L; Xiao L; Jiang W; Yang H; Hu D; Xia C; Li Y; Zhou C; Xiong Y; Liu L; Liao D; Guan R; Li K; Wang J; Zhang Y; Yang N; Mansfield AS Lung Cancer; 2020 Mar; 141():82-88. PubMed ID: 31982639 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective. Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714 [TBL] [Abstract][Full Text] [Related]
7. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J; Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714 [TBL] [Abstract][Full Text] [Related]
8. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876 [TBL] [Abstract][Full Text] [Related]
11. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803 [TBL] [Abstract][Full Text] [Related]
12. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062 [TBL] [Abstract][Full Text] [Related]
14. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. Lee K; Kim D; Yoon S; Lee DH; Kim SW Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716 [TBL] [Abstract][Full Text] [Related]
15. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627 [TBL] [Abstract][Full Text] [Related]
16. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475 [TBL] [Abstract][Full Text] [Related]
17. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756 [TBL] [Abstract][Full Text] [Related]
18. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma]. Ma XL; Jia RN; Han K; Zhang YX Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):578-584. PubMed ID: 38825903 [No Abstract] [Full Text] [Related]
19. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib. Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536 [TBL] [Abstract][Full Text] [Related]
20. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]